MEF2 in cardiac hypertrophy in response to hypertension.

Hypertension is a globally prevalent pathological condition and an underlying risk factor for the development of cardiac hypertrophy leading to heart failure. Myocyte enhancer factor 2 (Mef2) has been identified as one of the primary effectors of morphological changes in the hypertensive heart, as part of a complex network of molecular signaling controlling cardiac gene expression. Experimental chronic pressure-overload models that mimic hypertension in the mammalian heart lead to the activation of various pathological mechanisms that result in structural changes leading to debilitating cardiac hypertrophy and ultimately heart failure. The purpose here is to survey the literature implicating Mef2 in hypertension induced cardiac hypertrophy, towards illuminating points of interest for understanding and potentially treating heart failure. Copyright © 2022. Published by Elsevier Inc.

Citation

James D Cornwell, John C McDermott. MEF2 in cardiac hypertrophy in response to hypertension. Trends in cardiovascular medicine. 2023 May;33(4):204-212

Mesh Tags

Substances

PMID: 35026393

search → result